UFPT Stock Analysis: UFP Technologies | NASDAQ

Medical Devices | NASDAQ, USA | Market Cap: 2.107m USD | 12M Return: -6.2% | Charts, Fundamentals & Technical Analysis

Medical Devices, Sterile Packaging, Filtration, Protective Padding
Total Rating 52
Safety 74
Buy Signal -0.34
Medical Devices
Industry Rotation: +0.0
Market Cap: 2.11B
Avg Turnover: 52.6M
Risk 3d forecast
Volatility50.5%
VaR 5th Pctl8.82%
VaR vs Median6.04%
Reward TTM
Sharpe Ratio-0.02
Rel. Str. IBD45.8
Rel. Str. Peer Group50
Character TTM
Beta1.232
Beta Downside1.084
Hurst Exponent0.379
Drawdowns 3y
Max DD48.31%
CAGR/Max DD0.17
CAGR/Mean DD0.34
EPS (Earnings per Share) EPS (Earnings per Share) of UFPT over the last years for every Quarter: "2021-06": 0.62, "2021-09": 0.51, "2021-12": 0.42, "2022-03": 0.72, "2022-06": 0.57, "2022-09": 0.98, "2022-12": 1.1, "2023-03": 1.57, "2023-06": 1.57, "2023-09": 1.52, "2023-12": 1.51, "2024-03": 1.66, "2024-06": 1.86, "2024-09": 2.39, "2024-12": 2.46, "2025-03": 2.47, "2025-06": 2.5, "2025-09": 2.11, "2025-12": 2.44, "2026-03": 2.48,
EPS CAGR: 27.87%
EPS Trend: 96.0%
Last SUE: 1.13
Qual. Beats: 2
Revenue Revenue of UFPT over the last years for every Quarter: 2021-06: 50.655, 2021-09: 50.723, 2021-12: 56.343, 2022-03: 71.242, 2022-06: 94.343, 2022-09: 96.97, 2022-12: 91.237, 2023-03: 97.753, 2023-06: 100.037, 2023-09: 100.784, 2023-12: 101.497, 2024-03: 105.009, 2024-06: 110.177, 2024-09: 145.165, 2024-12: 144.07, 2025-03: 148.148, 2025-06: 151.176, 2025-09: 154.558, 2025-12: 148.915, 2026-03: 154.202,
Rev. CAGR: 22.47%
Rev. Trend: 97.2%
Last SUE: -0.13
Qual. Beats: 0

Warnings

Below Avwap Earnings

Tailwinds

Confidence

Seasonality 10.5 years of data

Jan -2.1% 15
Feb -3.6% 31
Mar +0.5% 11
Apr +1.0% 14
May +6.9% 34
Jun +1.0% 38
Jul -0.2% 8
Aug +0.0% 11
Sep -8.9% 27
Oct -4.1% 10
Nov +8.1% 52
Dec -0.1% 8

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.

Description: UFPT UFP Technologies

UFP Technologies, Inc. is a U.S.-based designer and manufacturer of engineered custom products serving multiple end markets, including medical, aerospace and defense, automotive, consumer, electronics, and industrial. The companys offerings span a wide range, from medical device components-such as protective drapes for robotic surgery, advanced wound care, surgical disposables, and packaging for orthopedic and cardiac implants-to industrial applications like filtration media, acoustic and thermal insulation, seals and gaskets, and equipment protection packaging. Additional product lines include uniform and tactical gear, sports and leisure components, and automotive trim and structural parts.

The company markets its products through a direct sales force and is headquartered in Newburyport, Massachusetts, having been founded in 1963. Classified within the Health Care sector under the Health Care Supplies sub-industry, UFPT operates as a diversified specialty manufacturer whose medical-focused product lines (including biopharma drug manufacturing and sterile packaging) coexist with industrial and defense-related operations, giving it exposure to both healthcare and broader industrial demand cycles.

Headlines to Watch Out For
  • Medical segment revenue grows on wound care and robotic surgery demand
  • Defense and aerospace packaging backlog expands on UAV orders
  • Acquisitions boost biopharma manufacturing capacity and margins
Piotroski VR-10 (Strict) 7.0
Net Income: 68.6m TTM > 0 and > 6% of Revenue
FCF/TA: 0.10 > 0.02 and ΔFCF/TA 1.11 > 1.0
NWC/Revenue: 24.16% < 20% (prev 23.01%; Δ 1.15% < -1%)
CFO/TA 0.12 > 3% & CFO 81.3m > Net Income 68.6m
Net Debt (154.5m) to EBITDA (116.3m): 1.33 < 3
Current Ratio: 2.91 > 1.5 & < 3
Outstanding Shares: last quarter (7.80m) vs 12m ago 0.30% < -2%
Gross Margin: 28.35% > 18% (prev 28.99%; Δ -0.64% > 0.5%)
Asset Turnover: 92.44% > 50% (prev 85.20%; Δ 7.23% > 0%)
Interest Coverage Ratio: 10.60 > 6 (EBIT TTM 92.6m / Interest Expense TTM 8.73m)
Altman Z'' 6.22
A: 0.22 (Total Current Assets 224.1m - Total Current Liabilities 77.0m) / Total Assets 674.7m
B: 0.58 (Retained Earnings 392.3m / Total Assets 674.7m)
C: 0.14 (EBIT TTM 92.6m / Avg Total Assets 658.7m)
D: 1.86 (Book Value of Equity 438.9m / Total Liabilities 235.8m)
Altman-Z'' = 6.22 = AAA
Beneish M -2.99
DSRI: 0.95 (Receivables 102.6m/96.9m, Revenue 608.9m/547.6m)
GMI: 1.02 (GM 28.99% / 28.35%)
AQI: 0.96 (AQ_t 0.52 / AQ_t-1 0.54)
SGI: 1.11 (Revenue 608.9m / 547.6m)
TATA: -0.02 (NI 68.6m - CFO 81.3m) / TA 674.7m)
Beneish M = -2.99 (Cap -4..+1) = A
What is the price of UFPT shares?

As of July 11, 2026, the stock is trading at USD 236.91 with a total of 281,726 shares traded. Over the past week, the price has changed by -13.02%, over one month by +1.91%, over three months by +17.72% and over the past year by -6.19%.

Current recommended Stop Loss: 221.50 (which is 6.5% or 1.4 ATR below the current price).

Is UFPT a buy, sell or hold?

UFP Technologies has received a consensus analysts rating of 3.75. Therefore, it is recommended to hold UFPT.

  • StrongBuy: 1
  • Buy: 1
  • Hold: 2
  • Sell: 0
  • StrongSell: 0

What are the forecasts/targets for the UFPT price?
Analysts Target Price 324.5 37%
UFP Technologies (UFPT) - Fundamental Data Overview as of 07 July 2026
Market Cap USD = 2.11b (2.11b USD * 1.0 USD.USD)
P/E Trailing = 30.95
P/E Forward = 21.8341
P/S = 3.461
P/B = 4.7887
P/EG = 3.8011
Revenue TTM = 608.9m USD
EBIT TTM = 92.6m USD
EBITDA TTM = 116.3m USD
Long Term Debt = 125.1m USD (from longTermDebt, last quarter)
Short Term Debt = 17.5m USD (from shortTermDebt, last quarter)
Debt = 174.5m USD (from shortLongTermDebtTotal, last quarter) + Leases 18.5m
Net Debt = 154.5m USD (calculated: Debt 174.5m - CCE 20.0m)
Enterprise Value = 2.26b USD (2.11b + Debt 174.5m - CCE 20.0m)
Interest Coverage Ratio = 10.60 (Ebit TTM 92.6m / Interest Expense TTM 8.73m)
EV/FCF = 32.57x (Enterprise Value 2.26b / FCF TTM 69.4m)
FCF Yield = 3.07% (FCF TTM 69.4m / Enterprise Value 2.26b)
FCF Margin = 11.41% (FCF TTM 69.4m / Revenue TTM 608.9m)
Net Margin = 11.27% (Net Income TTM 68.6m / Revenue TTM 608.9m)
Gross Margin = 28.35% ((Revenue TTM 608.9m - Cost of Revenue TTM 436.2m) / Revenue TTM)
Gross Margin QoQ = 28.77% (prev 28.18%)
Tobins Q-Ratio = 3.35 (Enterprise Value 2.26b / Total Assets 674.7m)
Interest Expense / Debt = 5.00% (Interest Expense 8.73m / Debt 174.5m)
Taxrate = 18.15% (15.2m / 83.8m)
NOPAT = 75.8m (EBIT 92.6m * (1 - 18.15%))
Current Ratio = 2.91 (Total Current Assets 224.1m / Total Current Liabilities 77.0m)
Debt / Equity = 0.40 (Debt 174.5m / totalStockholderEquity, last quarter 438.9m)
Debt / EBITDA = 1.33 (Net Debt 154.5m / EBITDA 116.3m)
Debt / FCF = 2.23 (Net Debt 154.5m / FCF TTM 69.4m)
Total Stockholder Equity = 413.0m (last 4 quarters mean from totalStockholderEquity)
RoA = 10.42% (Net Income 68.6m / Total Assets 674.7m)
RoE = 16.61% (Net Income TTM 68.6m / Total Stockholder Equity 413.0m)
RoCE = 17.20% (EBIT 92.6m / Capital Employed (Equity 413.0m + L.T.Debt 125.1m))
RoIC = 12.73% (NOPAT 75.8m / Invested Capital 595.2m)
WACC = 9.84% (E(2.11b)/V(2.28b) * Re(10.32%) + D(174.5m)/V(2.28b) * Rd(5.00%) * (1-Tc(0.18)))
Discount Rate = 10.32% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 77.78 | Cagr: 0.50%
[DCF] Terminal Value 73.29% ; FCFF base≈65.3m ; Y1≈74.8m ; Y5≈110.1m
[DCF] Fair Price = 149.5 (EV 1.31b - Net Debt 154.5m = Equity 1.16b / Shares 7.74m; r=9.84% [WACC]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 96.01 | EPS CAGR: 27.87% | SUE: 1.13 | # QB: 2
Revenue Correlation: 97.18 | Revenue CAGR: 22.47% | SUE: -0.13 | # QB: 0
EPS current Quarter (2026-06-30): EPS=2.56 | Chg30d=+1.89% | Revisions=+29% | Analysts=4
EPS next Quarter (2026-09-30): EPS=2.74 | Chg30d=+1.01% | Revisions=+29% | Analysts=4
EPS current Year (2026-12-31): EPS=10.38 | Chg30d=+2.52% | Revisions=+50% | GrowthEPS=+6.4% | GrowthRev=+6.2%
EPS next Year (2027-12-31): EPS=11.69 | Chg30d=+2.05% | Revisions=+50% | GrowthEPS=+12.5% | GrowthRev=+6.1%
[Analyst] Revisions Ratio: +59% (up=12, down=2)